Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer; Affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel Aviv, Israel.
The Safdié Institute for Cancer, AIDS and Immunology Research; Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
Clin Exp Immunol. 2021 Mar;203(3):375-384. doi: 10.1111/cei.13553. Epub 2020 Dec 8.
Despite undeniable improvement in the management of rheumatoid arthritis (RA), the discovery of more effective, less toxic and, ideally, less immune suppressive drugs are much needed. In the current study, we set to explore the potential anti-rheumatic activity of the non-toxic, tellurium-based immunomodulator, AS101 in an experimental animal model of RA. The effect of AS101 was assessed on adjuvant-induced arthritis (AIA) rats. Clinical signs of arthritis were assessed. Histopathological examination was used to assess inflammation, synovial changes and tissue lesions. Very late antigen-4 (VLA-4) cellular infiltration was detected using immunohistochemical staining. Enzyme-linked immunosorbent assay (ELISA) was used to measure circulating anti-cyclic citrullinated-peptide autoantibody (ACPA) and real-time polymerase chain reaction (PCR) was used to measure the in-vitro effect of AS101 on interleukin (IL)-6 and IL-1β expression in activated primary human fibroblasts. Prophylactic treatment with intraperitoneal AS101 reduced clinical arthritis scores in AIA rats (P < 0·01). AS101 abrogated the migration of active chronic inflammatory immune cells, particularly VLA-4 cells, into joint cartilage and synovium, reduced the extent of joint damage and preserved joint architecture. Compared to phosphate-buffered saline (PBS)-treated AIA rats, histopathological inflammatory scores were significantly reduced (P < 0·05). Furthermore, AS101 resulted in a marked reduction of circulating ACPA in comparison to PBS-treated rats (P < 0·05). Importantly, AS101 significantly reduced mRNA levels of proinflammatory mediators such as IL-6 (P < 0·05) and IL-1β (P < 0·01) in activated primary human fibroblasts. Taken together, we report the first demonstration of the anti-rheumatic/inflammatory activity of AS101 in experimental RA model, thereby supporting an alternative early therapeutic intervention and identifying a promising agent for therapeutic intervention.
尽管类风湿关节炎(RA)的治疗已有显著改善,但仍迫切需要发现更有效、毒性更低且理想情况下免疫抑制作用更小的药物。在本研究中,我们旨在探索基于无毒碲的免疫调节剂 AS101 在 RA 实验动物模型中的潜在抗风湿活性。评估了 AS101 对佐剂诱导性关节炎(AIA)大鼠的作用。评估关节炎的临床症状。采用组织病理学检查评估炎症、滑膜变化和组织损伤。通过免疫组织化学染色检测非常晚期抗原-4(VLA-4)细胞浸润。采用酶联免疫吸附试验(ELISA)测量循环抗环瓜氨酸肽自身抗体(ACPA),采用实时聚合酶链反应(PCR)测量 AS101 对激活的原代人成纤维细胞中白细胞介素(IL)-6 和 IL-1β表达的体外作用。腹腔内预防性给予 AS101 可降低 AIA 大鼠的临床关节炎评分(P<0·01)。AS101 阻止了活跃的慢性炎症免疫细胞,特别是 VLA-4 细胞,向关节软骨和滑膜的迁移,减少了关节损伤的程度并保持了关节结构。与磷酸盐缓冲盐水(PBS)处理的 AIA 大鼠相比,组织病理学炎症评分显著降低(P<0·05)。此外,与 PBS 处理的大鼠相比,AS101 导致循环 ACPA 明显减少(P<0·05)。重要的是,AS101 显著降低了激活的原代人成纤维细胞中促炎介质如 IL-6(P<0·05)和 IL-1β(P<0·01)的 mRNA 水平。综上所述,我们首次报道了 AS101 在实验性 RA 模型中的抗风湿/抗炎活性,从而支持早期治疗干预的替代方案,并确定了一种有前途的治疗干预药物。